MedTrace Logo

Therapeutic Study of ONO-4819CD for Ulcerative Colitis

NCT00296556 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2009-04-28

No results posted yet for this study

Summary

The purpose of this study is to investigate whether ONO-4819CD is safe and effective in the treatment of mild to moderate ulcerative colitis.

Conditions

Interventions

DRUG

Rivenprost (drug)

Sponsors & Collaborators

  • National Institute of Biomedical Innovation

    collaborator OTHER_GOV

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Shuh Narumiya, MD, PhD · Kyoto University, Graduate School of Medicine

  • Tsutomu Chiba, MD, PhD · Kyoto University, Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-12-31
Completion
2008-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00296556 on ClinicalTrials.gov